Pharmaceutical 3PL Market Projected to Reach $342 Billion by 2034

The global pharmaceutical third‑party logistics (3PL) market was valued at about USD 158.2 billion in 2025. Forecasts anticipate growth to USD 172.4 billion in 2026 and a rise to roughly USD 342.2 billion by 2034, reflecting a compound annual growth rate of 9 % over the 2026‑2034 period. North America accounted for the largest share in 2025, holding about 38.5 % of the market.

Growth drivers include continued vehicle production, stricter safety regulations, and expanding demand for advanced steering‑system components, especially as electric and hybrid vehicles gain market share. The sector also benefits from rising investments in cold‑chain infrastructure needed for biologics, vaccines and cell therapies.

Key players identified in the report are DHL Supply Chain (Germany), Kuehne + Nagel International AG (Switzerland), UPS Healthcare (U.S.), FedEx Corporation (U.S.), DB Schenker (Germany), CEVA Logistics (France), DSV A/S (Denmark), Nippon Express Holdings (Japan), Yusen Logistics (Japan), Maersk Logistics & Services (Denmark), SF Express (China) and several U.S. firms such as Robinson Worldwide and Hellmann Worldwide Logistics.